Overview

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment. After a run-in period on their current antipsychotic treatment, patients will be randomized to one of the four treatment arms as add-on therapy for a treatment duration of up to 3 months.
Phase:
Phase 2
Details
Lead Sponsor:
Amgen